The importance of CD40/CD154 costimulatory pathway blockade in immunosuppression
strategies is well-documented. Efforts are currently focused on monoclonal antibodies
specific for CD40 because of thromboembolic complications associated with monoclonal
antibodies directed towards CD154. Here we present the rational development and
characterization of a novel antagonistic monoclonal antibody to CD40. Rhesus macaques
were treated with the recombinant anti-CD40 mAb, 2C10, or vehicle before immunization …